Pharmacy

Include medication-assisted treatment high on the list of clinical tools used to treat opioid addiction.

ACA repeal or replacement must focus on how to preserve mental health services and pharmacy access.

New treatment indications are under investigation for the use of cannabinoid-based drugs.

The proliferation of specialty drugs has prompted new techniques for keeping costs in tow.

New treatment indications are under investigation for the use of cannabinoid-based drugs. Are you ready?

A Precision for Value survey highlights what can be done in order to encourage payers to ease coverage policies for these drugs in the next wave of HCV treatment.

Report highlights spending trends in key areas, including specialty medications, oncology, diabetes, and inflammatory conditions.

Scott Winiecki, MD, of the FDA Center for Drug Evaluation and Research, shares how the FDA is working to address the opioid epidemic.

How can physicians, already struggling to keep up with mounting regulations and larger patient loads, use PDMPs in more effective and efficient ways?

Experts share updates on new diabetes medications, and provide an overview of what’s coming.

A new report has troubling findings for payers, providers, and technology companies. Here are the key takeaways, and reactions from experts.

The proposed megamerger has been shot down. Find out what it means for healthcare execs.

Here are three pharmacy challenges facing healthcare executives and a two-pronged solution to help solve them.

Consider these tactics that analyze and address medical errors at a system level.

Cancer drug costs remain the most critical challenge in care, among other things.

HHS secretary nominee Tom Price has voiced opposition to bundled payments. One expert talks about mandatory and the possibility of voluntary bundled payments.

By deploying a proactive, year-round strategy that aligns data analytics with a focused approach for addressing gaps in care, your organization can turn routine quality measurement and reporting activities into a true strategic advantage by ensuring that quality measurably improves across key metrics.

Find out about the latest treatment and drug pipeline developments

High drug prices continue to plague payers, but various contributing factors intensify the problem.

Find out what’s in the drug pipeline for autoimmune disease.

The 21st Century Cures Act, a landmark medical research bill, offers healthcare executives a promising future.

Pharmaceutical manufacturer relationships and next-gen value based contracts are primed to accelerate value-derivation from your drug spend.

Experts share their ideas on how President-elect Trump could change the single largest source of insurance in the country.

Results from Managed Healthcare Executive’s annual State of the Industry Survey reveal which issues will hit managed healthcare hardest in 2017.

As more biosimilars are approved, plans and PBMs will continue to evolve their strategies regarding coverage and formulary management of these new medications.